Industry News Merck Endpoints News

Merck stops nemtabrutinib, the BTK inhibitor behind its $2.7B ArQule deal

  • Merck has ended development of nemtabrutinib (MK-1026), the main reason it bought ArQule for $2.7 billion in 2019.
  • The drug was in a slew of trials in blood cancers; Fierce Biotech's headline ties the decision to Phase 3 data.
  • Merck had earlier booked a write-down on the asset.
Points Based on public reports

This closes the book on one of Merck's weaker acquisitions: a non-covalent BTK inhibitor was meant to answer resistance to covalent drugs, but BTK degraders and strong incumbents narrowed the opening. For Merck, the loss is mostly sunk cost; the more telling point is how little the ArQule price bought beyond this molecule. Competitors in the non-covalent class, like Lilly's pirtobrutinib, face one fewer rival.